Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 378

Sort by

Sort Order Select

Journal Articles

A conceptual framework for managing iTTP

Richard J. Benjamin

Blood (2021) 137 (14): 1845–1846.

https://doi.org/10.1182/blood.2021011007

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Control of Hypercytokinemia in Critically Ill Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis with Plasma Exchange and Continuous Renal Replacement Therapy

Chengshuang Huang, Pei Huang, PhD, Xueqin Jiang, Hongbo Xu, Jian Lu, Runmei Tian, Ping Zhu, MD, Yan Chen, MD

Blood (2019) 134 (Supplement_1): 2335.

https://doi.org/10.1182/blood-2019-122529

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura

Jingrui (Jean) Sui, MD, Wenjing Cao, MD,PhD, Mohammad S. Abdelgawwad, MD, Konstantine Halkidis, MD PhD, Nicole K. Kocher, Bryan K. Guillory, MD, Lance A. Williams, III, MD, Marisa B. Marques, MD, Radhika Gangaraju, MD, X. Long Zheng, MD, PhD

Blood (2019) 134 (Supplement_1): 2456.

https://doi.org/10.1182/blood-2019-126093

Published: 2019

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Chris Wynick, MD MSc, BSc, Joanne Britto, MD BSc, Daniel Sawler, MD BSc, Arabesque Parker, MD, Mohammad Karkhaneh, PhD, Dawn Goodyear, MD, Haowei Linda Sun, MDFRCPC

Blood (2019) 134 (Supplement_1): 2379.

https://doi.org/10.1182/blood-2019-126354

Published: 2019

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Sindhu Malapati, MD, Sunny R K Singh, MD, Rohit Kumar, MD, Jason Mouabbi, MD, Tarik Hadid, MD MS

Blood (2019) 134 (Supplement_1): 2353.

https://doi.org/10.1182/blood-2019-129375

Published: 2019

Journal Articles

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Yuji Yamada, MD, Hiroyuki Ohbe, MD MPH, Hideo Yasunaga, MD PhD, Yoshitaka Miyakawa, MD PhD

Blood (2019) 134 (Supplement_1): 2374.

https://doi.org/10.1182/blood-2019-125170

Published: 2019

Journal Articles

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Blood (2019) 134 (Supplement_1): 90.

https://doi.org/10.1182/blood-2019-129383

Published: 2019

Journal Articles

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Gi June Min, MD, Hee-Je Kim, MD PhD, Sung-Soo Park, MD, Silvia Park, Young-Woo Jeon, MD PhD, Seung-Ah Yahng, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung Sik Cho, MD PhD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang-Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3260.

https://doi.org/10.1182/blood-2019-124275

Published: 2019

Journal Articles

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

Blood (2019) 134 (Supplement_1): 4986.

https://doi.org/10.1182/blood-2019-122106

Published: 2019

Journal Articles

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Phani Borra, MD, Cory Edward Mellon, MD

Blood (2019) 134 (Supplement_1): 4905.

https://doi.org/10.1182/blood-2019-128537

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Neel Belani, MD, Adriel Barrios-Anderson, Sc.B, A.B., William Rafelson, MDMBA, Matthew I. Quesenberry, MD, Rabin Niroula, MBBS

Blood (2019) 134 (Supplement_1): 4909.

https://doi.org/10.1182/blood-2019-123206

Published: 2019

Journal Articles

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Maria Cristina Pascual Izquierdo, PhD MD, Julio Del Rio-Garma, MD, Javier De La Rubia, Aurora Viejo, MD, Jesus Fernandez-Sojo, MD, Jesus Martin, MD, Xavier Solanich, MD, Faustino García-Candel, PhD MD, Luis Hernandez, MD, Marta Fernandez, MD, Ana Oliva, MD, Jose Maria Garcia-Gala, MD, Maria Eva Mingot-Castellano, PhD MD, Ines Gomez-Seguí, MD PhD, Rosa Goterris, MD, Michael Calviño, MD, María Luisa Antelo, MD PhD, Sol Sanchez, MD, Jose Antonio Moreno, MD, Cristina Amunarriz, MD, Jose Garcia-Arroba, MD, Carmen Fernandez, MD, Nieves Alonso, MD, Victoria Gonzalez, MD, Luisa Guerra, MD, M. Elena Moreno, MD, Moreno M. Dolores, MD, Gemma Moreno, MD, Melisa Daorta, MD, Esther Chica, MD, Rafael Del Orbe, MD PhD, Joan Cid, MD PhD, Margarita Berberana, MD, Carmen Ballester, MD, Sara Nistal Gil, MD, Julia Vidan, MD, Maite Calderon, MD, Consuelo Martinez Redondo, MD, Jose Carlos Hernandez, MD, Marina Gordillo, MD, Angel Salgado, Ramon Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 4910.

https://doi.org/10.1182/blood-2019-123258

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A conceptual framework for managing iTTP

Redefining outcomes in immune TTP: an international working group consensus report

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Control of Hypercytokinemia in Critically Ill Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis with Plasma Exchange and Continuous Renal Replacement Therapy

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Longitudinal Assessment of Plasma ADAMTS13 Biomarkers Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Plasma Exchange in Thrombotic Microangiopathy: Is It Time Sensitive?

Clinical Practice Pattern of Acquired Thrombotic Thrombocytopenic Purpura in Japan: A Nationwide Inpatient Database Analysis

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Validation of Recently Proposed Risk and Prognostic Factors for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Therapeutic Plasma Exchange in Pediatrics for Immunologic Disorders; Tolerated and Safe Process for Pediatric Life-Threatening Conditions

A Case of Mistaken Identity: TTP-like State Due to Heroin Overdose

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Incidence, Diagnosis, and Outcome of Acquired Thrombotic Thrombocytopenic Purpura (aTTP): A Nationwide Survey By the Spanish Apheresis Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only